This clinical-stage biopharmaceutical company focused on developing treatments for different kinds of cancers just recently launched an IPO, making it just the second IPO to launch in the U.S. since the coronavirus pandemic became the dominant issue. And while the author of today’s article acknowledges that this company “faces much of the challenges of a typical biotech IPO which means higher risk”, he argues that “there is a great deal to like about its potential and chances of success.” For more, CLICK HERE.